• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee.

作者信息

Arlett Peter, Portier Geraldine, de Lisa Roberto, Blake Kevin, Wathion Noel, Dogne Jean-Michel, Spooner Almath, Raine June, Rasi Guido

机构信息

European Medicines Agency, 7 Westferry Circus, Canary Wharf, London E14 4 HB, UK.

Federal Agency for Medicines and Health Products, Victor Horta Place, 40/40, 1060 Brussels, Belgium.

出版信息

Nat Rev Drug Discov. 2014 May;13(5):395-7. doi: 10.1038/nrd3713-c1. Epub 2014 Apr 22.

DOI:10.1038/nrd3713-c1
PMID:24751815
Abstract
摘要

相似文献

1
Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee.积极管理上市药品风险：欧洲药品管理局药物警戒风险评估委员会的经验
Nat Rev Drug Discov. 2014 May;13(5):395-7. doi: 10.1038/nrd3713-c1. Epub 2014 Apr 22.
2
Pharmacovigilance in Europe and North America: divergent approaches.欧洲和北美的药物警戒：不同的方法。
Soc Sci Med. 2012 Jul;75(1):165-70. doi: 10.1016/j.socscimed.2011.11.046. Epub 2012 Apr 3.
3
The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac.欧洲药品管理局在双氯芬酸监管行动中运用优先独立研究以获取最佳证据。
Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):431-4. doi: 10.1002/pds.3594. Epub 2014 Feb 25.
4
A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.欧洲药品管理局药物警戒风险评估委员会头18个月期间的信号描述。
Drug Saf. 2014 Dec;37(12):1059-66. doi: 10.1007/s40264-014-0240-1.
5
[Drug regulation in Spain].[西班牙的药品监管]
Med Clin (Barc). 1992 May 16;98(19):741-8.
6
Obstacles to transparency over pharmacovigilance data within the EMA.欧洲药品管理局（EMA）内部药物警戒数据透明度方面的障碍。
Prescrire Int. 2015 Nov;24(165):278-9.
7
The European Medicines Agency: a public health European agency?欧洲药品管理局：一个欧洲公共卫生机构？
Med Law. 2012 Mar;31(1):25-42.
8
Tooth-whitening directive finally being put to the vote.牙齿美白指令最终付诸表决。
J Ir Dent Assoc. 2010 Jun-Jul;56(3):122-3.
9
[Interpretation of Guidelines on Good Pharmacovigilance Practices for European Union].[欧盟药品不良反应监测规范解读]
Zhongguo Zhong Yao Za Zhi. 2013 Sep;38(18):2963-8.
10
Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.兽医药理学警戒。第1部分。欧盟的法律基础。
J Vet Pharmacol Ther. 2005 Apr;28(2):131-47. doi: 10.1111/j.1365-2885.2005.00645.x.

引用本文的文献

1
Trends in adverse drug reaction reporting in eight selected countries after the implementation of new pharmacovigilance regulation in 2012: a joinpoint regression analysis.2012年实施新的药物警戒法规后八个选定国家药物不良反应报告的趋势：一项Joinpoint回归分析
Eur J Clin Pharmacol. 2025 Jun 17. doi: 10.1007/s00228-025-03862-2.
2
The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System.基于强化欧盟系统 10 年回顾的未来药物警戒 STAR Compass 指南。
Drug Saf. 2024 Oct;47(10):941-956. doi: 10.1007/s40264-024-01451-3. Epub 2024 Jul 10.
3
Identifying Safety Subgroups at Risk: Assessing the Agreement Between Statistical Alerting and Patient Subgroup Risk.
识别有风险的安全亚组：评估统计警报和患者亚组风险之间的一致性。
Drug Saf. 2023 Jun;46(6):601-614. doi: 10.1007/s40264-023-01306-3. Epub 2023 May 2.
4
Pandemic vaccines: a formidable challenge for pharmacovigilance.大流行疫苗：药物警戒面临的巨大挑战。
Nat Rev Drug Discov. 2023 Jan;22(1):1-2. doi: 10.1038/d41573-022-00178-z.
5
Practical Implications From European Hospital Pharmacists on Prospective Risk Assessment for Medicine Shortages.欧洲医院药剂师对药品短缺前瞻性风险评估的实际影响
Front Med (Lausanne). 2020 Aug 5;7:407. doi: 10.3389/fmed.2020.00407. eCollection 2020.
6
Different Strategies to Execute Multi-Database Studies for Medicines Surveillance in Real-World Setting: A Reflection on the European Model.多数据库研究在真实世界环境下进行药物监测的不同策略：对欧洲模式的反思。
Clin Pharmacol Ther. 2020 Aug;108(2):228-235. doi: 10.1002/cpt.1833. Epub 2020 May 5.
7
Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands.药品安全问题在大众媒体中的报道：2001 年至 2015 年荷兰直接医疗保健提供者间通信的队列研究。
Drug Saf. 2020 Jul;43(7):677-690. doi: 10.1007/s40264-020-00922-7.
8
Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines.关于上市后和推出后证据生成的监管及卫生技术评估建议是药品全生命周期数据收集的基础。
Br J Clin Pharmacol. 2020 Jun;86(6):1034-1051. doi: 10.1111/bcp.14279. Epub 2020 Apr 24.
9
Measuring the impact of risk communications: Robust analytical approaches are key.衡量风险沟通的影响：稳健的分析方法是关键。
Br J Clin Pharmacol. 2020 Apr;86(4):635-636. doi: 10.1111/bcp.14222. Epub 2020 Feb 16.
10
Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee.初级保健健康数据库评估欧盟药品监测风险评估委员会讨论的药品的能力。
Clin Pharmacol Ther. 2020 Apr;107(4):957-965. doi: 10.1002/cpt.1775. Epub 2020 Feb 12.